Bristol Advisors LLC bought a new stake in STAAR Surgical Company (NASDAQ:STAA) during the second quarter, Holdings Channel reports. The institutional investor bought 20,000 shares of the medical instruments supplier’s stock, valued at approximately $216,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Palo Alto Investors LLC raised its position in STAAR Surgical by 2.6% in the first quarter. Palo Alto Investors LLC now owns 3,473,170 shares of the medical instruments supplier’s stock valued at $34,037,000 after buying an additional 86,925 shares during the period. Vanguard Group Inc. raised its position in STAAR Surgical by 1.5% in the first quarter. Vanguard Group Inc. now owns 1,272,972 shares of the medical instruments supplier’s stock valued at $12,475,000 after buying an additional 18,621 shares during the period. State Street Corp raised its position in STAAR Surgical by 6.3% in the fourth quarter. State Street Corp now owns 626,735 shares of the medical instruments supplier’s stock valued at $6,800,000 after buying an additional 37,175 shares during the period. Principal Financial Group Inc. raised its position in STAAR Surgical by 0.9% in the first quarter. Principal Financial Group Inc. now owns 295,129 shares of the medical instruments supplier’s stock valued at $2,893,000 after buying an additional 2,537 shares during the period. Finally, Geode Capital Management LLC raised its position in STAAR Surgical by 6.3% in the first quarter. Geode Capital Management LLC now owns 245,080 shares of the medical instruments supplier’s stock valued at $2,401,000 after buying an additional 14,420 shares during the period. 75.79% of the stock is currently owned by hedge funds and other institutional investors.

Shares of STAAR Surgical Company (STAA) opened at 11.80 on Wednesday. STAAR Surgical Company has a 12 month low of $7.45 and a 12 month high of $12.35. The company has a 50-day moving average price of $10.54 and a 200-day moving average price of $9.97. The company’s market capitalization is $485.07 million.

STAAR Surgical (NASDAQ:STAA) last issued its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported ($0.01) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.04. STAAR Surgical had a negative net margin of 6.06% and a negative return on equity of 8.69%. The business had revenue of $21.90 million during the quarter, compared to analyst estimates of $22.15 million. During the same period last year, the business posted ($0.02) earnings per share. STAAR Surgical’s quarterly revenue was up 4.8% compared to the same quarter last year. On average, equities analysts anticipate that STAAR Surgical Company will post ($0.11) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Bristol Advisors LLC Takes Position in STAAR Surgical Company (STAA)” was published by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.watchlistnews.com/bristol-advisors-llc-takes-position-in-staar-surgical-company-staa/1495371.html.

Several research analysts have recently weighed in on STAA shares. Zacks Investment Research lowered STAAR Surgical from a “hold” rating to a “sell” rating in a research report on Tuesday, May 9th. Canaccord Genuity lifted their price objective on STAAR Surgical from $9.00 to $11.00 and gave the stock a “hold” rating in a research report on Thursday, August 3rd. Benchmark Co. lifted their price objective on STAAR Surgical from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Monday. Finally, BidaskClub raised STAAR Surgical from a “strong sell” rating to a “sell” rating in a research report on Friday, August 11th.

About STAAR Surgical

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.

Want to see what other hedge funds are holding STAA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STAAR Surgical Company (NASDAQ:STAA).

Institutional Ownership by Quarter for STAAR Surgical (NASDAQ:STAA)

Receive News & Ratings for STAAR Surgical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical Company and related companies with Analyst Ratings Network's FREE daily email newsletter.